Versaflex HC - Syringe Plunger - Spanish FABRICANTE DE JERINGAS É M B O L O D E J E R I N G A D E S E C H A B L E • Cumplir con las normas USP VI e ISO 10993-4,5 • Esterilización con gamma y EtO • Rendimiento de sellado a largo plazo • Bajo coeficiente de fricción (COF) • Rendimiento uniforme en jeringas de diferentes diámetros • Ofreció una solución formulada que cumple con los requerimientos rigurosos de una aplicación médica • Mejoró la continuidad del suministro global • Aumentó la eficiencia del proceso al sustituir el material termoestable anterior con un TPE Versaflex™ HC 2110-57B REQUERIMIENTOS CLAVE ¿POR QUÉ AVIENT?

G L O B A L E L A S T I C & R U B B E R P R O D U C T M A N U FA C T U R E R T O U R N I Q U E T B A N D • Hardness 45, shore A • Thickness 0.5mm and Tensile set

E U R O P E A N M E D I C A L D E V I C E M A N U FA C T U R E R F A C E M A S K V E N T I L A T I O N V A L V E • ISO 9001 and USP VI compliant • Compatible with overmolding onto PP • Translucent and highly colorable • Soft touch • Provided valuable regulatory support and documentation, enabling faster internal trials and material qualification for this customer • Worked together with customer to select the best material from a broad portfolio of medical TPE grades • Trusted as a polymer supplier for multiple healthcare applications Dynaflex™ G2711 Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT?

Versaflex - MAM Cup - Spanish MAM T A Z A E N T R E N A D O R A - L E A R N T O D R I N K ™ • En cumplimiento de las normas de contacto con alimentos grasos de la Unión Europea* • Sensación de suavidad y tersura al tacto • Sin BPA, sin ftalatos • Gran facilidad de coloración • Ofreció una solución personalizada para cumplir con los Requerimientos de contacto con alimentos grasos y las necesidades de aplicación en Europa • Mejoró el atractivo para el cliente con un material suave, duradero y con color personalizado Versaflex™ FFC KEY REQUIREMENTS SOLUCIÓN AVIENT CUMPLE CON LA NORMATIVIDAD DE ALIMENTOS GRASOS MÁS INFORMACIÓN* Puede haber limitaciones: Consulte a Avient para obtener más información Copyright © 2020, Avient Corporation.

GLS TPE - Bayer Cap - Spanish BAYER® T A P A S O B R E - M O L D E A D A C O N E L A S T Ó M E R O T E R M O P L Á S T I C O ( T P E ) • Fácil de sujetar y abrir • Requerimientos de diseño: • Logotipo en relieve • Color específico de la marca • Optimiza el espacio en los estantes y reduce el embalaje • Funcionalidad de embalaje mejorada, tanto para el usuario (diseño ergonómico) como en el estante (mejor apilamiento y menos embalaje) • Se ofreció una formulación de valor agregado que permitió al cliente ampliar la diferenciación de la marca en el mercado Elastómero termoplástico GLS™ REQUERIMIENTOS CLAVE ¿POR QUÉ AVIENT?

PowerPoint Presentation P R O S T H E T I C S A N D O R T H O T I C S B R A N D K N E E R A I L & B R A C E • Replace metal to reduce weight • Update design to achieve slimmer design • Offer excellent strength and modulus properties • Improve durability with better fatigue resistance than incumbent aluminum • Increased design freedom and lightweighting for metal replacement applications while meeting structural needs • Delivered excellent fatigue endurance and moisture resistance for enhanced durability • Achieved cost reduction per part by switching to an injection molding process Complēt Long Carbon Fiber Reinforced Structural Thermoplastics WHY AVIENT?

PowerPoint Presentation M E D I C A L D E V I C E M A N U FA C T U R E R O S T O M Y B A G S E A L S • Comply with ISO 10993 and FDA Class II medical device regulations • Offer Good sealing performance • Provide technical supports for processing recommendations • Deliver a high compression set materials to improve comfort • Provided a medical-grade TPE to help the customer meet necessary regulatory specifications and gain market share • Provided technical support during design and the manufacturing process for EVA bonding • Delivered soft-touch feel and excellent sealing performance Versaflex HC Thermoplastic Elastomers - G2705 Formulation KEY REQUIREMENTS WHY AVIENT?

Microsoft PowerPoint - PolyOne Investor Presentation_Sidoti_3_19_13.pptx PolyOne Investor Presentation d d th l hSidoti and Company 17th Annual Emerging Growth  Institutional Investor Forum March 19, 2013 Forward – Looking Statements • In this presentation, statements that are not reported financial results or other historical information are “forward‐looking statements” within the meaning of  the Private Securities Litigation Reform Act of 1995.    The non‐GAAP financial measures  i l d dj t d EPS i b f i t t t d i ti dinclude: adjusted EPS, earnings before interest, tax, depreciation and  amortization (EBITDA), adjusted EBITDA, net debt, Specialty platform operating  income, Specialty platform gross margin percentage, adjusted operating income,  return on invested capital, net debt/ EBITDA, and the exclusion of corporate p p charges in certain calculations.  EPS: $1.20 Proforma Debt Maturities & Liquidity Summary – 12/31/12 (Reflecting  Financing & Spartech Acquisition) • Total Debt at 12/31/12 h $1,010 $297 $360 $300 $400 Debt Maturities  As of December  31, 2012  ($ millions) Less: Cash Net Debt 213 $797 $50 $297 $100 $200 • Available Liquidity Cash $213 $800 Debt Maturities  As of December  31, 2012 P f f 2/13 Fi i $50  $0 2015 2017 2020 Interest Rates: 7.500%                       5.000%                      7.375% Cash ABL Availability Total Liquidity $213 271 $484 $600 $400 $600 Proforma for 2/13 Financing ($ millions) Total Liquidity • Net Debt / EBITDA = 2.0x* $484 $50 $360 $0 $200 • Net Debt / EBITDA = 2.35x** $50$0 2015 2020 2023 Page 14 Interest Rates:   7.500%                      7.375%                      5.250% *Assumes $65 million of synergies related to Spartech acquistion **Assumes no synergies related to Spartech acquistion Use of Cash Share DividendsOrganic G Acquisitions • Repurchased 1 2 Repurchase • Introduced a Dividends • Expanding our Growth T t th t d Acquisitions • Repurchased 1.2 million shares in 2012 • 20.0 million shares are il bl f • Introduced a quarterly dividend in Q1 2011 and increased in Q1 2012 (25%) and Q1 2013 (20%) • Expanding our sales, marketing, and technical capabilities is top priority • Investing in • Targets that expand our: • Specialty offering • End market presence • Geographic footprint available for repurchase under the current authorization Q1 2013 (20%) • Objective of maintaining and growing Investing in operational and LSS initiatives (including synergy capture) • CAPEX • Synergy opportunities • Adjacent material solutions Proforma Cash Balance = $213M N t D bt / EBITDA* 2 0X CAPEX Net Debt / EBITDA* = 2.0X *Adjusted EBITDA assumes synergies related to the Spartech acquisition are realized at close; preliminary synergies estimated at $65M and are expected to be achieved over a 3-year period Page 15 Why Invest In PolyOne?

EXECUTIVE COMPENSATION EXECUTIVE COMPENSATION 2018 Summary Compensation Table Stock Awards (column (d)) Option Awards (column (e)) Name and Principal Position (a) Year (b) Salary ($) (c) Stock Awards ($) (d) Option Awards ($) (e) Non-Equity Incentive Plan Compensation ($) (f) All Other Compensation ($) (g) Total ($) (h) Lisa K. Garratt, Senior Vice President, Chief Commercial Officer Mark D. Other Benefits. 2018 Grants of Plan-Based Awards Target ($) (d) Estimated Future Payouts Under Equity Incentive Plan Awards Exercise or Base Price of Option Awards ($/Sh) (i) Threshold (#) (f) Estimated Future Payouts Under Non- Equity Incentive Plan Awards Name (a) Grant Date (b) Grant Date Fair Value of Stock and Option Awards ($) (j) Threshold ($) (c) Maximum ($) (e) All Other Stock Awards: Number of Shares of Stock or Units (#) (h) Target (#) (g) EXECUTIVE COMPENSATION Estimated Future Payouts Under Non-Equity Incentive Plan Awards (columns (c), (d) and (e)) (1) 2018 Annual Incentive Program Payments (2) Cash-Settled Performance Units.

D-2 The gate depth (D) should be 15% - 30% of the wall thickness at the gate entrance.